ClinicaliQ Trial Snapshot
- Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta — Active Not Recruiting • Phase III • NCT05972551.
- Romosozumab versus bisphosphonates for reducing fractures and improving bone density in children with osteogenesis imperfecta over 12 months.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months. Conditions: Osteogenesis Imperfecta Interventions: Romosozumab, Bisphosphonate Lead Sponsor: Amgen Planned Enrollment: 111 participants